HYPERTENSION IS A polygenic, heterogeneous disorder with a substantial environmental component. Although investigations into the genetic determinants of variation in blood pressure have found heritabilities ranging from ϳ30% to ϳ50% (72) , the vast majority of genetic loci responsible for this variation have thus far remained elusive. The use of biochemical or physiological traits that represent intermediate pathogenic steps in the development of hypertension, so-called "intermediate phenotypes," may aid in the discovery of hypertensionpredisposing loci (27, 42, 43, 62) . Because such traits are more likely to be influenced by the action of a single gene, they should be less prone to environmental influences that confound the genetic dissection of a complex trait such as hypertension.
Genes in a wide variety of biochemical pathways have been implicated in blood pressure control that are likely to influence a susceptibility to hypertension (42) . Of these pathways, those influencing the release of catecholamines may be some of the most important, because the release of catecholamines into the circulation is elevated not only in patients with essential hypertension but also in their normotensive first-degree relatives (16) . Catecholamine release is controlled, in part, by members of the chromogranin family of proteins (32, 34, 69) , which makes this family of proteins logical candidates for the exploration of sympathoadrenal activity in essential hypertension. The chromogranins comprise a family of acidic, soluble proteins that are stored in dense-core secretory granules throughout the endocrine and nervous systems and are coreleased by exocytosis with hormones, neurotransmitters, and neuropeptides (69) . Chromogranin A (CHGA) was first isolated from chromaffin cells of the adrenal medulla (6, 24) , whereas chromogranin B (CHGB) was initially characterized in a rat pheochromocytoma cell line (30) . Human CHGA and CHGB loci have been mapped to chromosomes 14q32 and 20pter-p12 (33) .
Several members of the chromogranin family undergo aggregation induced by low-pH and high-calcium levels. CHGA and CHGB form homodimeric complexes at pH 7.5, with progression to tetrameric stoichiometry at a secretory granule interior pH of 5.5 (80) . CHGB also binds calcium at high capacity (93 mol calcium/mol CHGB at pH 5.5) within secretory granules (80) . Chromogranins have been found to interact with other components of the matrix of the secretory granule, such as catecholamines, serotonin, and histamine, suggesting that they contribute to the formation of secretory granules (8, 21, 25, 73, 78) . CHGA, in particular, appears to be crucial for the formation of secretory granules and sequestration of hormones in neuroendocrine cells (28, 32) . Within chromaffin cells and sympathetic axons, CHGB may play a role in the sorting and trafficking of peptide hormone and neuropeptide precursors to secretory granules as well as an important role in granulogenesis (39) . In addition, an amino-terminal domain of CHGB binds to the secretory vesicle membrane (79) .
Chromogranins also have extracellular roles in the neuroendocrine system that are dependent on their functions as prohormones. Extensive posttranslational proteolytic processing at dibasic cleavage sites of CHGA and CHGB form biologically active peptides that have autocrine, paracrine, and endocrine activities. In humans, these granins are cleaved to produce a series of peptides: CHGA to vasostatins I and II [CHGA and CHGA (1) (60) ], which may play a role in the neuroendocrine/sympathoadrenal stress response to systemic infection, perhaps providing innate immunity (69) .
A role for CHGA in hypertension has been proposed, based on the tight coupling of the action of catecholamine on blood pressure and the CHGA-regulated formation of dense-core granules (71, 75) . CHGA is overexpressed in catecholaminergic cells in rodent models of genetic [spontaneously hypertensive rat (41, 48) ] and acquired [renovascular (60, 62) ] hypertension, suggesting augmented sympathoadrenal activity in the pathogenesis of these syndromes. Genetic ablation of the CHGA locus in the mouse results in dysregulated, elevated sympathochromaffin secretion and severe hypertension (32) . Thus, to identify candidate regions of the genome likely harboring loci contributing to hypertension susceptibility, we first assessed the genetic contribution to quantitative CHGA and CHGB expression by measuring the heritability of several circulating fragments. We then performed linkage analysis with genomic DNA markers at an ϳ5-cM density in 235 families. Finally, we coupled our heritability and linkage results with our in vitro studies of catecholamine and chromogranin release.
METHODS

Sample.
A sample of 742 individuals, constituting 235 nuclear families with 405 possible sibling pairs and 968 parent-offspring pairs, was recruited from southern California. The protocol was approved by the University of California-San Diego Institutional Review Board, and each subject gave written informed consent. The average family consisted of four individuals in two generations; 149 of these families were collected as part of a twin sample collection (81), 91 of which contained a self-reported monozygotic twin pair and 58 of which contained a self-reported dizygotic twin pair. When available, parents and additional siblings were also collected to form nuclear families. For these analyses, one twin from each monozygotic twin pair was removed before the genotyping, whereas all dizygotic twin pairs remained in the sample. After the genotyping, the zygosity of all self-reported dizygotic twin pairs was confirmed before sib-pair linkage analyses. The remaining 86 families in the sample were collected as nuclear families. The number of possible sibling pairs that could be formed per nuclear family ranged from 1 to 36 [given by (n) ϫ (n Ϫ 1)/2]. Ethnicity was defined by self-identification of the ethnicity of the subject's four grandparents. Of these families, 160 were Caucasian (of European ancestry), 22 were Hispanic (MexicanAmerican), 21 were African-American, and 32 were of other ethnicities or of mixed ancestry. The ages of the offspring in the sample ranged from 14 to 78 yr with a mean of 37.5 yr. One hundred twenty-five families (ϳ53%) had a positive family history for hypertension (in a first-degree relative before the age of 60 yr), 82 families had a negative family history, and 28 families had an indeterminate/ unknown family history (43, 44) ; 545 individuals were normotensive and 88 individuals were hypertensive with 109 individuals, primarily parents, having missing data. None of the subjects had a history of renal failure.
Genotyping. Microsatellite genotyping of all individuals was performed by the National Heart, Lung, and Blood Institute Mammalian Genotyping Service at the Center for Medical Genetics, Marshfield Clinic, Marshfield, WI. Microsatellite markers were from screening sets 13 and 52. Genetic map positions for the 730 autosomal markers, which had an average intermarker distance of ϳ5 cM, were also provided by the Marshfield Clinic (http://research.marshfieldclinic. org/genetics). The genotype data were curated and Mendelian errors were identified using the Pedstats module of Merlin (3). The program Graphical Representation of Relationships (GRR) was used to confirm family relationships and twin zygosity (2) . Among the 742 individuals genotyped, there was a 9.8% missing genotype data rate and 1.9% apparent genotyping error rate as identified by Mendelian inconsistencies in the genotypes.
Biochemical phenotyping. EDTA-anticoagulated plasma was obtained from each subject and stored at Ϫ70°C before being assayed. Chromogranin region-specific radioimmunoassays based on synthetic peptides were performed as previously described (55) (56) (57) (58) (59) .
125 I radiolabeling of each peptide was enabled by either an endogenous or adventitious (terminal) tyrosine residue. Polyclonal rabbit antisera were developed to the synthetic chromogranin regions as previously described (45, 58, 59) .
Statistical analyses. Because variance-components approaches are not robust to departures from multivariate normality, we attempted to correct this to the extent possible for our phenotypes (5) . The values for CHGB312-331 and CHGB439-451 were multiplied by 10 to increase the SD above 0.5, as suggested in the documentation for sequential oligogenic linkage analysis routines (SOLAR) (4). The trait values for CHGA116-439 were all log transformed and multiplied by 10 to reduce the kurtosis below 0.8 and increase the standard deviation above 0.5. Only values for the transformed phenotypes are reported. The values for CHGA361-372 were relatively normally distributed and thus remained unchanged.
Heritability (h r 2 ) estimates were obtained via the variance component methodology implemented in the SOLAR version 2.1.2 linkage analysis package (4). This maximum likelihood method assumes a multivariate normal distribution of phenotypes in a pedigree and can accommodate a defined set of covariates (49, 50) . The null hypothesis of no heritability (h r 2 ϭ 0) is tested by comparing a "full" model, which assumes that some fraction of the phenotypic variation is explained by genetic factors, with a "reduced" model, which assumes that no variation is explained by genes, using likelihood ratio tests. Covariates (age and gender) that were significant in the heritability analysis were retained and considered in the linkage analyses.
Two-point and multipoint quantitative trait linkage analyses of the microsatellite marker data were conducted using the SOLAR package, which employs a variance-component-based algorithm. Missing genotypes are imputed and assessed probabilistically by conditioning on all other linked marker data and pedigree structure, and the proportion of marker alleles shared identical by descent among all relative pairs is estimated independently for all autosomal markers. Linkage is assessed by fitting a polygenic model that does not incorporate genotype information provided by marker loci and comparing it with models that incorporate genotype data either with a specific marker (two-point analysis) or with multiple markers (multipoint). The log (base 10) of the ratio of the likelihoods of the marker-specific and polygenic models is the log of the odds (LOD) score, a traditional measure of genetic linkage. Because there are many different methodologies that can be used to assess linkage for quantitative traits, we also took advantage of the regression-based method implemented in the software Merlin-regress of the Merlin linkage analysis package (3, 53) . We felt it necessary to incorporate both SOLAR and Merlin because there are advantages and disadvantages to each method. For example, Merlin-regress has been shown to be more robust to issues involving incomplete marker informativity (10, 17, 51, 52) .
Bivariate genetic ( G) and environmental (E) correlations were computed for pairs of phenotypes using SOLAR. G represents the genetic correlation [the cross-product of the h 2 values for any two phenotypes or the coefficient of shared genetic determination, a measure of pleiotropy], whereas E is the environmental correlation (13) . We tested two hypotheses for genetic correlations: whether there was evidence for pleiotropy ( G significantly different from 0) and whether or not the pleiotropy was complete (G significantly different from 1). When convergent linkages were observed for single traits, bivariate linkage analyses were also run for those traits in combination, within SOLAR.
CHGA and CHGB secretion assays. PC12 cells grown in 10-cm plates were incubated (in duplicates) with mock buffer versus the secretagogues nicotine (Sigma, 60 M), pituitary adenylate cyclaseactivating polypeptide (PACAP; Calbiochem, 0.2 M), or BaCl 2 (2 mM) in 3 ml release buffer [150 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 10 mM HEPES (pH 7); in the case of stimulation by BaCl2, the release buffer did not contain CaCl2] for 30 min.
For studies of CHGA and CHGB secretion, the release medium was collected and centrifuged at 1,000 rpm for 5 min to remove any suspended cells, the supernatant was transferred into a polypropylene tube, and an equal volume (3 ml) of 1% trifluroacetic acid (TFA; Sigma) was added. The mixture was loaded onto an equilibrated (by washing with 1 ml of 100% acetonitrile once, followed by 3 ml of 1% TFA three times) C-18 Sep column (Peninsula Laboratories; San Carlos, CA). After the column was washed with 3 ml of 1% TFA three times, proteins were eluted with 3 ml of 60% acetonitrile-1% TFA into a polypropylene tube. The eluant was frozen in dry ice-ethanol bath and evaporated to dryness by a lyophilizer. The lyophilized sample was dissolved in 100 l of SDS-PAGE sample buffer (Invitrogen), 15 l of each sample were run on a 10% polyacrylamide gel, and proteins were transferred to a nitrocellulose membrane for immunoblot detection of CHGA and CHGB. The membrane was blocked in Tris-buffered saline (TBS) containing 5% nonfat milk and 0.1% Tween 20 for 1 h at room temperature, followed by incubation with a goat polyclonal antibody (Santa Cruz Biotechnology, 1:300 dilution) raised against the COOH-terminal 20 amino acids of human CHGA overnight at 4°C. After being washed, the membrane was incubated with a donkey anti-goat IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnology, 1:5,000 dilution) for 1 h, followed by chemiluminescent detection of CHGA bands by Supersignal West Pico reagent (Pierce). The membrane was stripped, and CHGB bands were detected using a goat polyclonal antibody (Santa Cruz Biotechnology, 1:300 dilution) raised against the COOH-terminal 19 amino acids of human CHGB, following the same method as CHGA. The relative intensities of the bands were measured using NIH ImageJ (version 1.31) software, and the stimulated secretion values were expressed with respect to mock secretion of CHGA and CHGB.
As a control for this chromogranin secretion experiment, the same batch of PC12 cells was subjected to [ 3 H]norepinephrine secretion assays as described previously (38, 69, 70) using the same stimuli for the same period of time (30 min).
CHGA and CHGB transcription assays. To probe the regulation of CHGA and CHGB biosynthesis, we used a transfected chromogranin promoter/luciferase reporter system, as previously described (30, 63, 64, 66, 77) . We expressed promoter/reporter plasmids with a 1,133-bp mouse CHGA promoter (77) or a 1,303-bp mouse CHGB promoter (33) in PC12 cells in the presence or absence of secretory stimulation by three chromaffin cell secretogogues: the nicotinic cholinergic agonist nicotine (63, 66) and the PAC1 G protein-coupled receptor (GPCR) agonist PACAP (22, 63, 64, 68) . After 48 h, cell lysates were harvested for assays of luciferase reporter activity and cellular protein content, as described above. Table 1 reports the descriptive statistics and heritability estimates for each phenotype. All biochemical phenotypes were relatively normally distributed after transformation. Heritability estimates for all CHGA and CHGB fragments were highly significant (P Ͻ 0.0001) and ranged from 0. 45 Of the LOD peaks observed for CHGA 361-372 and CHGB 439 -452 , four peaks were significant at the genome-wide level using SOLAR. Because these two chromogranin fragments had very high heritabilities, and sib-pair linkage power varies directly with trait heritability (Ref. 48 ; http://statgen. iop.kcl.ac.uk/gpc/), the higher resolution of the CHGA 361-372 and CHGB 439 -452 LOD peaks in these linkage analyses is perhaps not unexpected. However, only one of these linkage peaks retained statistical significance at the genome-wide level using Merlin-regress.
RESULTS
Heritability.
Bivariate (pleiotropic) linkage analyses. CgA 361-372 and CgB 439 -451 mapped to approximately the same regions on chromosomes 2 and 13. Because these two phenotypes were also found to be genetically correlated (Table 2) , we conducted bivariate linkage analysis for these phenotypes using SOLAR in an effort to improve evidence for linkage and increase the resolution. The results of the univariate and bivariate analyses are shown in Fig. 1 All locations are in cM, and the intervals listed for the multipoint linkage analyses are the 1-log of the odds (LOD) intervals in cM surrounding each peak with a LOD score Ͼ2.0. SOLAR, sequential oligogenic linkage analysis routines. resulted in a maximum LOD score of 3.08 at 74 cM. Although the G value between CgB 312-331 and CgB 439 -451 did not reach statistical significance in this sample using SOLAR, bivariate linkage of these two phenotypes resulted in a maximum LOD score of 3.39 at 74 cM.
Coordinate control of secretion and transcription of CHGA and CHGB. To test whether chromaffin cell stimuli such as nicotine, PACAP, and BaCl 2 activate secretion of CHGA and CHGB simultaneously, we treated PC12 chromaffin cells with these secretagogues (vs. mock stimulation) and analyzed the release media by immunoblot analysis. As shown in Fig. 3 , nicotine (acting at the physiological control point for secretion, the nicotinic cholinergic receptor) stimulated secretion of CHGA and CHGB by 3.37 Ϯ 0.17-and 17.46 Ϯ 0.59-fold, respectively; PACAP (acting on its PAC1 GPCR) activated secretion of CHGA and CHGB by 1.57 Ϯ 0.08-and 4.89 Ϯ 0.16-fold, respectively; and Ba 2ϩ (blocking cell surface K ϩ channels and thereby depolarizing the cell membrane) triggered secretion of CHGA and CHGB by 4.55 Ϯ 0.26-and 17.59 Ϯ 0.51-fold, respectively. Thus the rank order of efficacy of secretagogues to activate exocytotic corelease of both CHGA and CHGB was Ba 2ϩ Ͼ nicotine Ͼ PACAP. This observation is consistent with the rank order of their effects on norepinephrine secretion. Thus several chromaffin cell secretagogues functioning through very different upstream targets and signaling pathways (see Fig. 5 ) coordinately stimulate cosecretion of catecholamines as well as the peptides CHGA and CHGB.
Using transfected promoter/reporter plasmids, we tested whether the biosynthesis of CHGA and CHGB was similarly controlled by secretory stimulation. As shown in Fig. 4 , both PACAP and nicotine stimulated transcription of both CHGA and CHGB, and, in each case, the rank order of potency was PACAP Ͼ nicotine. This rank order contrasts with the effects of the same stimuli on secretion, in which nicotine Ͼ PACAP (Fig. 3) . It is apparent that both PACAP and nicotine stimulate transcription of both CHGA and CHGB, but PACAP is a more powerful trigger to transcription (of either CHGA or CHGB) than is nicotine. 
DISCUSSION
Overview. These data provide evidence that circulating peptides derived from members of the chromogranin family display high levels of heritability (up to ϳ91%, CHGB 439 -451 ; Table 1 ), and their concentrations reveal significant G values as well as genetic linkage to markers on several chromosomes. Evidence for pleiotropy was first suggested by analysis of the G for chromogranin peptides in our sample (Table 2 ). In particular, CHGA 361-372 and CHGB 439 -451 showed especially significant evidence for G . Because these peptides also gave evidence for linkage to the same regions on chromosomes 2, 7, and 13, we performed bivariate linkage analysis on composite traits formed from these two peptides, which yielded higher LOD scores than linkage for either of the individual traits considered alone (Table 4 and Figs. 1 and 2 ). Because the genes encoding CHGA and CHGB reside on chromosomes 14q32 and 20pter-p12, respectively (34), these pleiotropic regions must represent trans-quantitative trait loci (QTLs) affecting CHGA/CHGB biosynthesis or secretion, likely by regulating efferent sympathetic outflow (Fig. 5) .
Genetic complexity. Contrary to expectation, we did not observe cis-QTLs for CHGA/CHGB peptide expression at the CHGA/CHGB loci themselves. We (74) have already studied polymorphism at the human CHGA locus and documented the effect of promoter variants on CHGA release into the bloodstream. However, the relative power of linkage (effect of a locus on a trait during meiotic cosegregation) versus association (effect of a particular allele on a trait in a population) may be quite different, depending on the degree of trait-determining locus heterogeneity (across the genome) versus allelic heterogeneity (at a locus); indeed, association may be considerably more powerful than linkage in many circumstances (47) . However, linkage (the approach in this study) does offer the advantage of genome-wide searching with a relatively small number of markers (typically ϳ400 -800 microsatellites).
While significant, the G values between CHGA and CHGB fragments in plasma (e.g., CHGA 116 -439 with CHGB 439 -451 , G ϭ 0.531, P Ͻ 0.01) were less than complete (i.e., substantially Ͻ1). This is, perhaps, not unexpected considering that after initial synthesis, CHGA and CHGB are subject to further posttranslational modification in the form of proteolytic cleavage (7, 12, 21) to generate the fragments recognized by immunoassays, and such cleavage varies among the chromogranins from tissue site to site (7, 21) .
While G values for fragment concentrations between CHGA/CHGB peptide pairs were typically significant (e.g., CHGA 116 -439 with CHGB 439 -451 , G ϭ 0.531, P Ͻ 0.01), G values for peptide pairs within CHGA (CHGA 116 -439 with CHGA 361-372 , G ϭ 0.097) or within CHGB (CHGB [313] [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] [327] [328] [329] [330] [331] with CHGB 439 -451 , G ϭ 0.172) were typically not significant (Table 2) . Apparently the relatively high interchromogranin G values reflect coordinate/shared genetic control of biosynthesis/release, whereas the relatively low intrachromogranin G values reflect the influence of other factors on each trait, such as shared environment (e.g., CHGA 116 -439 with CHGA 361-372 , E ϭ Ϫ0.649, P Ͻ 0.01). Indeed, the negative sign on this E value is consistent with the typical inverse relationship seen between the plasma concentrations of CHGA 116 -439 and CHGA [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] [371] [372] (43, 57) , likely representing interindividual differences in the degree of proteolytic processing of the CHGA precursor into the catestatin product (12, 70) .
Potential cellular mechanisms of pleiotropy. What might be the mechanism of such shared genetic determination (or G )? We found that CHGA, CHGB, and catecholamines were co- released by exocytotic secretory stimuli of chromaffin cells with similar rank orders of secretagogue efficacy (Ba 2ϩ Ͼ nicotine Ͼ PACAP; Fig. 4 ). CHGA and CHGB also displayed shared transcriptional control in chromaffin cells, once again with similar rank orders of stimulus efficacy (this time: PACAP Ͼ nicotine; Fig. 4) . Transcriptional activation by secretory stimuli illustrates the concept of "stimulus-transcription coupling" (or "stimulus-secretion-synthesis coupling"), a process whereby the secretory cell replenishes the just-released transmitters that we have described for the individual members of the chromogranin family (31, 35, 63, 64) . Figure 5 synthesizes these results and illustrates potential control points for coordinate control of CHGA and CHGB biosynthesis and secretion, which, in turn, might suggest candidate processes or genetic loci for pleiotropy. For example, a QTL influencing efferent preganglionic sympathetic tone to sympathochromaffin cells would be expected to perturb both synthesis and secretion of CHGA and CHGB. Alterations in the elements of the intracellular signal transduction pathways whereby chromaffin cell secretogogues (acetylcholine and PACAP) activate either transmitter exocytosis or resynthesis would also represent logical possible sites for a pleiotropic QTL. Our pleiotropic human linkage results (Figs. 1 and 2 and Table 4 ) do not allow us to distinguish among the multiple possible mechanisms underlying such pleiotropy, nor to distinguish whether the mechanism(s) governing trans-QTL-mediated cosecretion of CHGA and CHGB is predominantly at the level of exocytosis or transcription (or both). Of note, elevated sympathetic tone is frequently described in human hypertension as well as the first-degree relatives of patients with the syndrome (42, 62) . In rodent genetic models of hypertension, sympathetic tone and chromogranin expression are also deranged (18, 19, 41) , and an early increase in sympathetic activity may cosegregate with later increased blood pressure in rat genetic hypertension (27) .
CHGA 361-372 is representative of the catestatin fragment of CHGA, which inhibits the release of catecholamines from sympathoadrenal chromaffin cells by blocking the neuronal nicotinic receptor, the physiological trigger for secretion (34, 54, 68) . Catestatin also prevents the desensitization of catecholamine release from chromaffin cells that is induced by repeated nicotinic agonist stimulation (35) . Catestatin may thus contribute to an autocrine negative-feedback mechanism that regulates catecholamine release within the sympathoadrenal system. Because excess sympathetic activity has been implicated in the development of hypertension (42), a disturbance of the catestatin mechanism may be a contributing factor. Indeed, recent studies have shown a decrease in plasma catestatin levels in patients with hypertension as well as in normotensive individuals with genetic risk for hypertension (43) , and catestatin replacement "rescues" the elevated blood pressure in the hypertensive mouse CHGA targeted ablation model (32). Although catestatin levels were reduced in these individuals, plasma CHGA levels and catecholamine excretion were augmented, suggesting a possible processing defect of CHGA (40, 61) . Thus a novel QTL influencing catestatin production could have implications for autonomic control of the circulation and hence for the development of hypertension.
Positional candidate genetic loci. An examination of the regions beneath the CHGA 361-372 and CHGB 439 -451 bivariate linkage peaks on chromosomes 2, 7, and 13 provides evidence for positional candidate genes that might influence exocytosis, based on neural expression or involvement in secretion or receptor signal transduction. The 1-LOD interval within the linkage region on chromosome 2 (2p25.2-25.1, 14 -24 cM, ϳ6.7-10.6 Mb) contained 17 genes, one of which (YWHAQ, 14-3-3 protein ) is an activator of the rate-limiting step in catecholamine biosynthesis (tyrosine hydroxylase). The 1-LOD interval beneath the peak on chromosome 7 (7p13-11.22, 66 -85 cM, ϳ44 -70 Mb) contained 74 genes, 6 of which are potential candidate genes: soluble NSF attachment receptor protein Ykt6 (a potential mediator of exocytosis), calcium/calmodulin-dependent protein kinase type II ␤-chain, DOPA decarboxylase (in the catecholamine biosynthetic pathway), calcitonin gene-related peptide receptor component protein, potassium channel tetramerization domain containing 7, and calneuron 1 (a calcium-binding protein). There were 20 genes located beneath the 1-LOD interval under the linkage peak on chromosome 13 (13q31.2-32.3, 68 -80 cM, ϳ88 -99 Mb), 2 of which suggested candidate gene status: probable GPCR 80 and Ras-related protein Rap-2a. Feitosa et al. (15) also found linkage of chromosomes 7 and 13 to body mass index.
This is the initial report on genome-wide linkage for multiple chromogranin fragments. Our previous CHGB 312-331 link- Fig. 5 . Pleiotropy: potential pathways, mechanisms, and candidates. Coordinate control of CHGA and CHGB biosynthesis and exocytotic secretion in chromaffin cells is illustrated in response to the physiological secretory stimuli acetylcholine (ACh) and PACAP. Points of shared physiological control suggest gene products whose encoding loci can be examined for polymorphism to explain the observed pleiotropy. nAChR, nicotinic ACh receptor; ER, endoplasmic reticulum; PAC1R, PACAP PAC1 receptor.
age scan in the UGRP/CEPH extended pedigrees (23) found a LOD peak on chromosome 11, which was not replicated in this sample. However, neither of these two clinical samples was randomly sampled from the population, and the two samples differed in ascertainment criteria. The UGRP/CEPH pedigrees were collected based on the availability of very large sibships (typically 6 -12 siblings), coupled initially with the availability of both parents and all four grandparents (11, 22, 23, 37, 76) . Such criteria are likely to select for healthy families with considerable longevity and against chronic disease with associated premature mortality. In contrast, our family sample was ascertained in the setting of a blood pressure study (81) with ϳ16% of the subjects already diagnosed with hypertension and another ϳ36% at genetic risk of developing hypertension by virtue of positive family history. Thus the two different samples (Utah and San Diego) likely differ substantially in genetic predisposition toward cardiovascular disease and hence autonomic function (42) .
Perspectives. In summary, these studies provide evidence for coordinate genetic control of exocytosis of multiple sympathochromaffin cell cotransmitters. Figure 5 summarizes our findings and proposes a model for neuronal and endocrine cellular events, both secretory and transcriptional, likely to give rise to our observations. These results have implications for heritable autonomic control of the circulation and the genetic basis of cardiovascular diseases such as systemic hypertension.
